Not logged in
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
SaveSubgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)
Tsurutani, J.; Jacot, W.; Yamashita, T.; Riaz, F.; Yerushalmi, R.; Im, S-A.; Niikura, N.; Halser-Strub, U.; Cortes, J.; Wennstig, A-K.; Chae, Y.; Wang, X.; Li, W.; Simon, H.; Masci, G.; Tamburini, E.; Aguilar, C. Orbegoso; Tecson, K.; Yung, L.; Modi, S.
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save
Share
Save